Trials / Active Not Recruiting
Active Not RecruitingNCT05615415
Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 (PASC) Using TSPO Positron Emission Tomography (PET) and MRI
Assessment of Immunological and Vascular Dysfunction in Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 (PASC) Using TSPO PET and MRI
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (actual)
- Sponsor
- NYU Langone Health · Academic / Other
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- —
Summary
The overarching goal of this study is to develop PET/MR techniques for the diagnosis of neuropsychiatric post-acute sequelae (PASC) of SARS-CoV-2. The central hypothesis is that immunological and cerebrovascular dysfunction after acute SARS-CoV-2 infections mediate neuropsychiatric PASC (NP-PASC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PET Tracer | Standard radiopharmaceutical injected via intravenous catheter during PET-MR scanning. |
| DRUG | MRI Tracer | Injected via intravenous catheter during PET-MR scanning. |
| DEVICE | 3T PET/MRI | Used to evaluate neuroinflammation and cerebrovascular measures. Some MRI image acquisitions will employ work in progress (WIP) sequences, including ASL (Arterial Spin Labeling), Diffusion and T2-weighted EPI (DT2W), Golden-angle radial sparse parallel (GRASP) DCE-MRI, and Magnetization Transfer (MT) imaging. |
Timeline
- Start date
- 2022-02-15
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2022-11-14
- Last updated
- 2025-11-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05615415. Inclusion in this directory is not an endorsement.